Immunosuppressant drugs such as corticosteroids, cyclooxygenase inhibitors, interferon alpha may be effective. A 2020 review reported that canakinumab was "an effective long-term treatment with a favorable safety profile in patients with Schnitzler syndrome".In June 2018 NHS England published a Clinical Commissioning Policy: Anakinra to treat periodic fevers and autoinflammatory disorders (all ages) which stated that "Anakinra
may be used as a first line treatment in patients with a documented diagnosis of Schnitzler syndrome".Because anakinra is so highly and rapidly effective for inducing complete remission of Schnitzler syndrome, it has been suggested that in patients who do not respond to anakinra, the diagnosis should be reconsidered. Anakinra is not curative, however; symptoms recur soon after treatment stops. Outcomes
Generally treatment with anakinra prevents outbreaks but they resume if treatment is stopped. In around 15-20% of people, a lymphoproliferative disorder as a complication, most commonly Waldenströms macroglobulinemia, develops. AA amyloidosis has also been reported in people with Schnitzler syndrome.The life span in patients with Schnitzler syndrome has not been shown to differ much from the general population. Epidemiology
It is a rare condition; as of September 2014, 281 cases had been reported and as of 2017 around 300 cases had been reported. History
The disease is named after the French dermatologist Liliane Schnitzler who first described this syndrome in 1972. A Delphi study on the taxonomy and definition of auto-inflammatory diseases, published in 2018, considered the alternative name "late onset gammopathy with recurrent urticaria and fever" but this received little support. See also
List of skin conditions

References


== External links ==
Clindamycin/tretinoin is a topical gel used in the treatment of acne. The two active ingredients are the antibiotic clindamycin phosphate (1.2%) and tretinoin (0.025%), a retinoid. The two active ingredients perform different functions, the clindamycin is active against gram-positive bacteria, including streptococci and penicillin-resistant staphylococci. The Tretinoin element acts to reduce the amount of oil released by oil glands in skin as well as encouraging skin cell replenishment. The topical treatment is stored in 2, 30, and 60 gram tubes and should be stored at 25°C (77°F), with the tube tightly shut away from light. Side effects may include peeling, redness, dryness, itching and photosensitivity. Also, topical clindamycin may rarely cause diarrhea or colitis. Sun exposure while using this preparation can cause skin irritation. Citations
External links
Official Website